GK-1 Improves the Immune Response Induced by Bone Marrow Dendritic Cells Loaded with MAGE-AX in Mice with Melanoma
Open Access
- 30 October 2014
- journal article
- research article
- Published by Wiley in Journal of Immunology Research
- Vol. 2014, 1-12
Abstract
The aim of dendritic cell (DC) vaccination in cancer is to induce tumor-specific effector T cells that may reduce and control tumor mass. Immunostimulants that could drive a desired immune response are necessary to be found in order to generate a long lasting tumor immune response. GK-1 peptide, derived fromTaenia crassiceps, induces not only increase in TNFα, IFNγ, and MCP-1 production in cocultures of DCs and T lymphocytes but also immunological protection against influenza virus. Moreover, the aim of this investigation is the use of GK-1 as a bone marrow DCs (BMDCs) immunostimulant targeted with MAGE antigen; thus, BMDC may be used as immunotherapy against murine melanoma. GK-1 induced in BMDCs a meaningful increment of CD86 and IL-12. In addition, the use of BMDCs TNFα/GK-1/MAGE-AX induced the highest survival and the smallest tumors in mice. Besides, the treatment helped to increase CD8 lymphocytes levels and to produce IFNγin lymph nodes. Moreover, the histopathological analysis showed that BMDCs treated with GK-1/TNFαand loaded with MAGE-AX induced the apparition of more apoptotic and necrotic areas in tumors than in mice without treatment. These results highlight the properties of GK-1 as an immunostimulant of DCs and suggest as a potential candidate the use of this immunotherapy against cancer disease.Keywords
Funding Information
- Universidad Nacional Autónoma de México (PAPIIT-DGAPA IN225805, IN214109, 50396)
- Universidad Nacional Autónoma de México (PAPIIT-DGAPA IN225805, IN214109, 50396)
- Secretaría de Ciencia, Humanidades, Tecnología e Innovación (PAPIIT-DGAPA IN225805, IN214109, 50396)
This publication has 51 references indexed in Scilit:
- Cancer immunotherapy via dendritic cellsNature Reviews Cancer, 2012
- Type I interferon is selectively required by dendritic cells for immune rejection of tumorsJournal of Experimental Medicine, 2011
- Heterologous Prime-Boost Oral Immunization with GK-1 Peptide from Taenia crassiceps Cysticerci Induces Protective ImmunityClinical and Vaccine Immunology, 2011
- Hematopoietic differentiation and production of mature myeloid cells from human pluripotent stem cellsNature Protocols, 2011
- Dendritic cells and immunity against cancerJournal of Internal Medicine, 2010
- Toll-Like Receptor AgonistsThe Cancer Journal, 2010
- Towards Identification of the Mechanisms of Action of Parasite-Derived Peptide GK1 on the Immunogenicity of an Influenza VaccineClinical and Vaccine Immunology, 2009
- How Diverse--CD4 Effector T Cells and their FunctionsJournal of Molecular Cell Biology, 2009
- Adoptive cell transfer: a clinical path to effective cancer immunotherapyNature Reviews Cancer, 2008
- Cytokines in cancer pathogenesis and cancer therapyNature Reviews Cancer, 2004